Arcutis Biotherapeutics, Inc.
ARQT
Jodie situation report
Arcutis Biotherapeutics, Inc.'s move is being confirmed by its market group.
ARQT accounts for 6.1% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
IMNM, MIRM, BLTE moved materially before ARQT. ARQT crossed its material path threshold at 15:35 ET. DYN followed.
- Revenue increased 59.3% versus the comparable filing period.
- Cash declined 38.6M versus the comparable period.
14 of 18 members in Biotech Rare Diseases are active. 0 of 8 disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind ARQT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
WLKWestlake CorporationpartnerFeb 25, 2026 ▾
“Contractual Obligations and Contingent Liabilities The following summarizes our significant contractual obligations as of December 31, 2025: Facility Operating Lease We lease a facility in Westlake Village, California under an operating lease that commenced i…”
ABBVAbbVie Inc.competitorFeb 25, 2026 ▾
“For psoriasis, our primary competitors include: • injected biologic therapies such as Skyrizi®, marketed by AbbVie Inc., and Bimzelex®, marketed by UCB, Inc.; • non-injectable systemic therapies used to treat plaque psoriasis such as Otezla, marketed by Amgen…”
Depended on by
SLRCSLR Investment Corp.investeeFeb 24, 2026 ▾
“Net unrealized gain for the fiscal year ended December 31, 2025 was primarily due to appreciation in the value of our investments in KBH Topco, LLC, SLR Business Credit, RD Holdco, Inc., Bayside Parent, LLC and Arcutis Biotherapeutics, Inc., among others, par…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARQT is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.